What is USANA Health Sciences' operating income?

USANA Health Sciences' total operating income in 2025 was $37.43 million, based on the following breakdown: Total Gross Profit: $724.41 million Total Operating Expenses: $686.97 million

USANA Health Sciences (USNA) Financials

$21.49 -0.02 (-0.09%)

Closing price 07/2/2026 03:59 PM Eastern

Extended Trading

$21.00 -0.49 (-2.26%)

As of 07/2/2026 04:10 PM Eastern

Compare

Annual Income Statements for USANA Health Sciences

This table shows USANA Health Sciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	12/31/2022	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Net Income / (Loss) Attributable to Common Shareholders	95	100	63	126	-622	125	69	69	64	42	11
Consolidated Net Income / (Loss)	95	100	63	126	101	125	69	69	64	42	11
Net Income / (Loss) Continuing Operations	95	100	63	126	-622	125	69	69	64	42	11
Total Pre-Tax Income	143	139	135	192	150	178	109	109	102	76	42
Total Operating Income	142	139	133	188	146	176	108	108	93	66	37
Total Gross Profit	759	826	868	989	873	926	805	805	744	693	724
Total Revenue	918	1,006	1,047	1,189	1,061	1,135	999	999	921	855	925
Operating Revenue	918	1,006	1,047	1,189	1,061	1,135	999	999	921	855	925
Total Cost of Revenue	160	180	179	201	188	209	194	194	177	161	201
Operating Cost of Revenue	160	180	179	201	188	209	194	194	177	161	201
Total Operating Expenses	617	687	735	800	1,454	749	697	697	651	627	687
Selling, General & Admin Expense	209	234	265	275	268	261	262	262	257	263	337
Other Operating Expenses / (Income)	408	453	470	525	727	488	435	435	394	364	336
Impairment Charge	-	-	-	-	-	-	-	-	0.00	0.00	6.97
Restructuring Charge	-	-	-	-	-	-	-	-	0.00	0.00	6.46
Total Other Income / (Expense), net	0.93	-0.07	2.14	3.16	8.61	1.46	1.01	1.01	9.38	10	4.10
Interest Expense	0.02	0.44	0.05	0.04	0.07	0.51	0.19	0.19	0.26	0.28	0.84
Interest & Investment Income	1.12	1.48	2.19	4.43	4.71	2.54	3.79	3.79	9.64	11	2.42
Other Income / (Expense), net	-0.17	-1.11	-0.00	-1.23	3.97	-0.57	-2.59	-2.59	0.01	-1.01	2.52
Income Tax Expense	48	39	72	65	50	53	39	39	39	34	30
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	-	-	-	-	0.00	-	0.00	0.03	0.72
Basic Earnings per Share	$3.72	$4.14	$2.57	$5.24	$4.44	$5.89	$3.60	$3.60	$3.31	$2.20	$0.58
Weighted Average Basic Shares Outstanding	25.46M	24.19M	24.35M	24.11M	22.64M	21.16M	19.25M	19.25M	19.25M	19.10M	18.54M
Diluted Earnings per Share	$3.59	$3.99	$2.53	$5.12	$4.41	$5.86	$3.59	$3.59	$3.30	$2.19	$0.58
Weighted Average Diluted Shares Outstanding	26.36M	25.05M	24.71M	24.64M	22.82M	21.26M	19.31M	19.31M	19.35M	19.16M	18.57M
Weighted Average Basic & Diluted Shares Outstanding	25.40M	24.20M	24.30M	24.10M	22.82M	21.26M	-	19.29M	18.90M	-	18.46M

This table shows USANA Health Sciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	1/3/2026	4/4/2026
Net Income / (Loss) Attributable to Common Shareholders	11	17	17	10	11	4.45	9.40	9.66	-6.52	-1.78	7.52
Consolidated Net Income / (Loss)	11	17	17	10	11	4.48	9.29	10	-6.66	-1.60	6.96
Net Income / (Loss) Continuing Operations	11	17	17	10	11	4.48	9.29	10	-6.66	-1.60	6.96
Total Pre-Tax Income	21	27	27	20	19	10	17	19	1.79	4.18	15
Total Operating Income	18	24	25	18	16	8.21	16	17	1.22	3.82	14
Total Gross Profit	171	179	185	173	161	175	197	186	165	177	191
Total Revenue	213	221	228	213	200	214	250	236	214	226	250
Operating Revenue	213	221	228	213	200	214	250	236	214	226	250
Total Cost of Revenue	43	42	43	40	39	39	52	50	49	49	59
Operating Cost of Revenue	43	42	43	40	39	39	52	50	49	49	59
Total Operating Expenses	153	155	160	155	145	167	181	169	164	173	177
Selling, General & Admin Expense	63	59	64	64	61	73	91	82	86	78	88
Other Operating Expenses / (Income)	90	96	96	90	84	94	90	87	78	81	89
Total Other Income / (Expense), net	2.92	2.39	2.44	2.36	3.01	2.22	1.07	2.10	0.57	0.36	1.59
Interest Expense	0.04	0.15	0.05	0.05	0.05	0.13	0.41	0.26	0.05	0.12	0.24
Interest & Investment Income	2.73	2.91	2.68	2.76	3.14	2.74	0.72	0.62	0.58	0.50	0.44
Other Income / (Expense), net	0.23	-0.37	-0.19	-0.35	-0.09	-0.39	0.76	1.74	0.04	-0.01	1.39
Income Tax Expense	9.18	9.85	11	9.77	8.00	5.95	7.45	8.37	8.46	5.77	8.51
Net Income / (Loss) Attributable to Noncontrolling Interest	-	-	0.00	0.00	0.00	0.03	-0.11	0.79	-0.14	0.18	-0.56
Basic Earnings per Share	$0.59	$0.88	$0.86	$0.55	$0.56	$0.23	$0.49	$0.52	($0.36)	($0.07)	$0.41
Weighted Average Basic Shares Outstanding	19.25M	19.25M	19.17M	19.07M	19.08M	19.10M	19.05M	18.51M	18.29M	18.54M	18.40M
Diluted Earnings per Share	$0.59	$0.87	$0.86	$0.54	$0.56	$0.23	$0.49	$0.52	($0.36)	($0.07)	$0.41
Weighted Average Diluted Shares Outstanding	19.37M	19.35M	19.30M	19.16M	19.08M	19.16M	19.09M	18.54M	18.29M	18.57M	18.41M
Weighted Average Basic & Diluted Shares Outstanding	19.13M	18.90M	19.05M	19.05M	19.06M	0.00	18.62M	18.27M	18.28M	18.46M	18.46M

This table details how cash moves in and out of USANA Health Sciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	12/31/2022	12/31/2022	12/30/2023	12/28/2024	1/3/2026
Net Change in Cash & Equivalents	32	40	61	-33	20	78	48	48	42	-149	-23
Net Cash From Operating Activities	111	137	124	152	127	160	104	104	71	61	22
Net Cash From Continuing Operating Activities	111	137	124	152	127	163	104	104	71	61	22
Net Income / (Loss) Continuing Operations	95	100	63	126	101	125	69	69	64	42	11
Consolidated Net Income / (Loss)	95	100	63	126	101	125	69	69	64	42	11
Depreciation Expense	9.98	13	16	17	15	14	13	13	13	15	33
Non-Cash Adjustments To Reconcile Net Income	11	17	18	16	16	15	20	20	25	24	29
Changes in Operating Assets and Liabilities, net	-4.27	6.71	27	-7.05	-12	0.56	-6.41	-6.41	-31	-20	-50
Net Cash From Investing Activities	-25	-32	-13	-69	47	-34	-12	-12	-12	-213	-10
Net Cash From Continuing Investing Activities	-25	-32	-13	-69	47	-34	-12	-12	-12	-213	-10
Purchase of Property, Plant & Equipment	-24	-33	-13	-11	-17	-15	-10	-17	-14	-10	-14
Acquisitions	-	-	-	-	-	0.00	-6.53	-	0.00	-203	0.00
Purchase of Investments	-	-	-	-86	-1.66	-21	0.00	0.00	-1.27	-0.87	-1.07
Sale of Property, Plant & Equipment	0.19	0.01	0.02	0.38	0.02	0.01	0.01	0.01	0.02	0.06	3.91
Sale and/or Maturity of Investments	-	0.81	0.30	28	66	2.22	4.56	4.56	3.78	1.13	0.00
Other Investing Activities, net	-1.58	-0.01	-	-	-	-	-	-	0.00	0.00	0.87
Net Cash From Financing Activities	-49	-65	-50	-105	-152	-59	-30	-30	-14	9.55	-41
Net Cash From Continuing Financing Activities	-49	-65	-50	-105	-152	-59	-30	-30	-14	9.55	-41
Repayment of Debt	-	-74	-3.50	0.00	-5.07	-60	-11	-11	-0.75	-1.47	-27
Repurchase of Common Equity	-61	-65	-50	-105	-150	-57	-25	-25	-12	-9.44	-28
Payment of Dividends	-	-	-	-	-	-	-	-	0.00	0.00	-1.75
Issuance of Debt	-	74	3.50	0.00	5.00	60	11	11	1.54	24	18
Other Financing Activities, net	12	-	-0.32	0.10	-1.99	-2.37	-4.71	-4.71	-3.43	-3.22	-2.35
Effect of Exchange Rate Changes	-5.10	-	-	-	-	11	-14	-14	-2.50	-6.19	5.11
Cash Interest Paid	0.02	0.32	0.02	0.01	0.01	0.71	0.05	0.05	0.07	0.08	0.66

This table details how cash moves in and out of USANA Health Sciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/28/2024	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	1/3/2026	4/4/2026
Net Change in Cash & Equivalents	6.88	-167	-2.14	4.07	33	-183	-2.14	-28	-5.97	13	4.42
Net Cash From Operating Activities	22	16	18	7.99	30	5.79	15	12	-1.96	-3.39	9.76
Net Cash From Continuing Operating Activities	22	16	18	7.99	30	5.79	15	12	-1.96	-3.39	9.76
Net Income / (Loss) Continuing Operations	11	-4.96	17	10	11	4.48	9.29	10	-6.66	-1.60	6.96
Consolidated Net Income / (Loss)	11	-4.96	17	10	11	4.48	9.29	10	-6.66	-1.60	6.96
Depreciation Expense	3.27	4.75	3.16	3.81	3.57	4.00	8.34	7.74	7.92	8.56	8.28
Amortization Expense	1.89	1.96	1.93	1.89	1.99	-	1.91	-	-	-	1.51
Non-Cash Adjustments To Reconcile Net Income	4.12	2.38	5.01	3.92	3.90	11	4.09	8.25	0.27	16	4.77
Changes in Operating Assets and Liabilities, net	1.61	12	-8.95	-12	9.47	-8.20	-8.14	-12	-8.91	-21	-12
Net Cash From Investing Activities	-1.45	-208	-4.07	-1.55	-2.34	-205	-3.88	-4.16	-3.20	1.11	-2.60
Net Cash From Continuing Investing Activities	-1.45	-208	-4.07	-1.55	-2.34	-205	-3.88	-4.16	-3.20	1.11	-2.60
Purchase of Property, Plant & Equipment	-1.45	-2.90	-3.20	-2.67	-2.40	-1.80	-2.80	-5.03	-3.20	-2.80	-2.65
Purchase of Investments	-	0.40	-0.87	-	-	-	-1.07	-	-	-	0.00
Sale of Property, Plant & Equipment	-	0.05	0.00	-	0.06	-	0.00	-	-	3.91	0.05
Net Cash From Financing Activities	-12	24	-12	-1.35	-0.08	23	-14	-39	-0.98	13	-3.64
Net Cash From Continuing Financing Activities	-12	24	-12	-1.35	-0.08	23	-14	-39	-0.98	13	-3.64
Repayment of Debt	-	-0.72	-	-	0.00	0.01	0.00	-	-	-2.00	-4.00
Repurchase of Common Equity	-12	2.16	-9.44	-	-	-	-12	-15	-	-	0.00
Payment of Dividends	-	-	-	-	-	-	0.00	-	-0.88	-0.49	-1.38
Issuance of Debt	-	23	0.54	0.15	-0.00	23	0.00	1.60	-	16	4.00
Other Financing Activities, net	-0.04	0.07	-3.04	-0.03	-0.08	-0.07	-2.17	-0.02	-0.10	-0.06	-2.27
Effect of Exchange Rate Changes	-2.26	0.37	-3.81	-1.02	5.45	-6.81	0.72	2.31	0.17	1.91	0.90
Cash Interest Paid	0.00	0.07	0.02	0.05	0.00	0.00	0.05	0.61	-	0.00	0.24
Cash Income Taxes Paid	7.14	4.51	9.10	17	6.69	-	7.77	18	6.21	-	9.11

This table presents USANA Health Sciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2022	2023	2024	2025
Period end date	1/3/2015	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	12/31/2022	12/28/2024	12/28/2024	1/3/2026
Total Assets	351	423	471	519	554	517	641	597	748	748	743
Total Current Assets	191	244	278	340	392	329	425	384	279	279	288
Cash & Equivalents	111	143	176	247	214	235	312	288	182	182	158
Accounts Receivable	-	-	-	-	-	-	-	-	-	-	4.29
Inventories, net	45	66	65	63	82	69	90	67	70	70	103
Prepaid Expenses	35	35	37	30	33	26	23	29	28	28	23
Plant, Property, & Equipment, net	71	88	101	103	92	95	100	98	95	95	94
Total Noncurrent Assets	88	91	92	76	70	92	115	114	374	374	360
Goodwill	18	17	17	17	17	17	17	17	144	144	138
Intangible Assets	41	38	34	35	32	30	31	32	152	152	133
Noncurrent Deferred & Refundable Income Taxes	5.93	9.84	18	2.86	3.35	3.09	4.64	9.80	20	20	27
Other Noncurrent Operating Assets	24	25	22	21	18	43	62	55	59	59	62
Total Liabilities & Shareholders' Equity	351	423	471	519	554	517	641	597	748	748	743
Total Liabilities	120	142	145	156	163	165	199	162	162	162	157
Total Current Liabilities	109	131	138	141	149	136	168	144	140	140	129
Short-Term Debt	-	-	-	-	-	-	-	0.00	23	23	14
Accounts Payable	7.78	10	9.04	12	9.95	13	18	11	12	12	17
Other Current Liabilities	101	121	129	129	139	124	150	133	105	105	97
Total Noncurrent Liabilities	12	11	6.86	15	15	29	31	18	22	22	28
Noncurrent Deferred & Payable Income Tax Liabilities	11	9.82	5.50	14	13	10	12	4.07	4.07	4.07	4.89
Other Noncurrent Operating Liabilities	1.11	1.15	1.37	1.15	1.26	19	19	14	18	18	23
Redeemable Noncontrolling Interest	-	-	-	-	-	-	-	-	54	54	53
Total Equity & Noncontrolling Interests	230	281	325	363	391	352	442	434	532	532	533
Total Preferred & Common Equity	230	281	325	363	391	352	442	434	532	532	533
Total Common Equity	230	281	325	363	391	352	442	434	532	532	533
Common Stock	62	70	72	77	72	59	62	56	76	76	84
Retained Earnings	166	215	265	288	330	306	383	392	479	479	466
Accumulated Other Comprehensive Income / (Loss)	2.13	-3.78	-12	-1.43	-10	-14	-3.63	-13	-23	-23	-16

This table presents USANA Health Sciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	10/1/2022	4/1/2023	7/1/2023	9/30/2023	3/30/2024	6/29/2024	9/28/2024	3/29/2025	6/28/2025	9/27/2025	4/4/2026
Total Assets	556	606	603	601	629	631	671	747	735	727	739
Total Current Assets	341	396	388	390	421	419	451	281	262	264	294
Cash & Equivalents	247	295	300	307	328	332	365	180	151	145	163
Accounts Receivable	-	-	-	-	-	-	-	-	-	-	9.66
Inventories, net	67	64	62	60	61	62	64	74	83	91	96
Prepaid Expenses	27	36	26	23	32	25	22	28	27	28	25
Plant, Property, & Equipment, net	95	97	96	95	98	98	98	94	97	96	95
Total Noncurrent Assets	120	113	119	116	110	115	122	371	376	366	350
Goodwill	17	17	17	17	17	17	17	144	144	144	138
Intangible Assets	32	32	30	29	29	29	29	147	143	138	129
Noncurrent Deferred & Refundable Income Taxes	13	7.87	16	15	11	18	17	19	26	24	25
Other Noncurrent Operating Assets	57	56	57	54	53	51	59	61	63	60	58
Total Liabilities & Shareholders' Equity	556	606	603	601	629	631	671	747	735	727	739
Total Liabilities	145	150	134	131	129	119	138	163	149	145	144
Total Current Liabilities	126	130	114	113	113	104	115	137	122	119	117
Short-Term Debt	-	-	-	-	1.32	0.00	0.00	23	0.00	0.00	14
Accounts Payable	10	11	9.27	9.32	8.27	6.65	7.04	14	18	16	16
Other Current Liabilities	115	120	105	103	103	97	108	100	104	102	87
Total Noncurrent Liabilities	19	20	20	18	17	15	23	25	27	26	27
Noncurrent Deferred & Payable Income Tax Liabilities	4.80	5.58	4.80	4.75	5.11	4.65	4.73	4.80	4.66	4.47	5.06
Other Noncurrent Operating Liabilities	14	14	15	13	12	11	19	21	23	22	22
Redeemable Noncontrolling Interest	-	-	-	-	-	-	-	54	54	53	51
Total Equity & Noncontrolling Interests	411	455	469	470	500	512	533	530	531	528	544
Total Preferred & Common Equity	411	455	469	470	500	512	533	530	531	528	544
Total Common Equity	411	455	469	470	500	512	533	530	531	528	544
Common Stock	52	56	60	62	65	69	72	75	76	80	85
Retained Earnings	379	410	427	428	453	464	474	478	474	467	473
Accumulated Other Comprehensive Income / (Loss)	-20	-11	-18	-20	-19	-21	-14	-23	-19	-19	-14

This table displays calculated financial ratios and metrics derived from USANA Health Sciences' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	1/2/2016	12/31/2016	12/30/2017	12/29/2018	12/28/2019	1/2/2021	12/31/2022	12/31/2022	12/30/2023	12/28/2024	1/3/2026
DEI Shares Outstanding	12,769,551.00	12,193,500.00	23,992,549.00	23,976,585.00	21,643,055.00	21,037,938.00	-	-	-	19,059,572.00	18,280,857.00
DEI Adjusted Shares Outstanding	51,078,204.00	48,774,000.00	23,992,549.00	23,976,585.00	21,643,055.00	21,037,938.00	-	-	-	19,059,572.00	18,280,857.00
DEI Earnings Per Adjusted Shares Outstanding	1.85	2.05	2.61	5.26	-28.76	5.93	-	-	-	2.21	0.59
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	16.20%	9.54%	4.09%	13.56%	-10.79%	6.95%	-11.99%	-15.83%	-7.77%	-7.22%	8.28%
EBITDA Growth	22.06%	-0.31%	-1.58%	37.25%	-15.10%	14.59%	-36.28%	-33.59%	-8.80%	-24.51%	-9.19%
EBIT Growth	22.73%	-2.81%	-3.65%	41.22%	-19.75%	17.15%	-40.30%	-37.55%	-11.37%	-29.83%	-38.83%
NOPAT Growth	22.26%	6.42%	-38.51%	101.72%	-21.34%	26.62%	-44.43%	-40.87%	-15.66%	-36.95%	-71.69%
Net Income Growth	23.53%	5.67%	-37.49%	101.85%	-20.36%	24.01%	-44.37%	-40.47%	-8.02%	-34.06%	-72.71%
EPS Growth	23.53%	11.14%	-36.59%	102.37%	-13.87%	32.88%	-38.74%	-37.35%	-8.08%	-33.64%	-73.52%
Operating Cash Flow Growth	5.97%	22.81%	-9.58%	22.90%	-16.69%	26.57%	-35.22%	-14.29%	-41.30%	-13.66%	-63.36%
Free Cash Flow Firm Growth	4.17%	16.92%	7.66%	33.65%	-25.91%	17.80%	79.11%	-131.45%	-189.05%	116.34%	-110.90%
Invested Capital Growth	15.63%	8.62%	-22.36%	-2.41%	3.18%	10.99%	0.00%	0.00%	192.75%	0.00%	3.35%
Revenue Q/Q Growth	0.52%	2.06%	1.97%	2.23%	-2.55%	3.58%	0.00%	0.00%	-0.74%	-0.87%	0.00%
EBITDA Q/Q Growth	2.46%	-1.89%	3.64%	6.31%	5.29%	2.30%	0.00%	0.00%	3.53%	-22.14%	0.00%
EBIT Q/Q Growth	2.21%	-2.67%	3.48%	7.05%	0.66%	2.73%	0.00%	0.00%	2.73%	-19.71%	0.00%
NOPAT Q/Q Growth	2.19%	-1.72%	-30.99%	43.22%	-1.83%	7.22%	0.00%	0.00%	4.55%	-24.44%	0.00%
Net Income Q/Q Growth	2.90%	-2.04%	-30.72%	43.37%	-1.54%	7.66%	0.00%	0.00%	6.64%	-22.60%	0.00%
EPS Q/Q Growth	2.90%	-5.45%	-31.99%	41.05%	-4.13%	8.72%	0.00%	0.00%	6.80%	-22.61%	0.00%
Operating Cash Flow Q/Q Growth	-0.75%	15.34%	-0.01%	-8.82%	13.74%	-4.65%	0.00%	0.00%	-28.31%	-24.91%	0.00%
Free Cash Flow Firm Q/Q Growth	1.20%	32.32%	2.70%	-11.59%	14.55%	-18.63%	0.00%	0.00%	0.00%	-15.94%	98.51%
Invested Capital Q/Q Growth	-1.12%	-14.25%	-32.14%	-0.77%	-11.14%	17.19%	0.00%	0.00%	161.81%	154.20%	1.30%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	82.61%	82.09%	82.87%	83.12%	82.33%	81.57%	80.58%	80.58%	80.82%	81.13%	78.29%
EBITDA Margin	16.49%	15.01%	14.19%	17.15%	16.32%	17.49%	12.66%	12.66%	12.52%	9.34%	7.84%
Operating Margin	15.42%	13.78%	12.65%	15.84%	13.78%	15.55%	10.78%	10.78%	10.11%	7.76%	4.05%
EBIT Margin	15.40%	13.67%	12.65%	15.73%	14.15%	15.50%	10.52%	10.52%	10.11%	7.64%	4.32%
Profit (Net Income) Margin	10.31%	9.94%	5.97%	10.61%	9.48%	10.99%	6.94%	6.94%	6.93%	4.92%	1.24%
Tax Burden Percent	66.40%	72.20%	46.45%	65.91%	66.80%	70.06%	63.85%	63.85%	62.26%	55.09%	27.64%
Interest Burden Percent	100.78%	100.75%	101.61%	102.35%	100.22%	101.15%	103.42%	103.42%	110.07%	116.90%	103.94%
Effective Tax Rate	33.61%	27.80%	53.55%	34.09%	33.20%	29.94%	36.15%	36.15%	37.74%	44.91%	72.36%
Return on Invested Capital (ROIC)	73.29%	69.71%	46.34%	108.25%	84.85%	100.27%	0.00%	94.09%	20.20%	8.55%	2.38%
ROIC Less NNEP Spread (ROIC-NNEP)	72.80%	69.74%	45.87%	107.46%	83.73%	99.90%	0.00%	93.64%	17.59%	5.07%	1.63%
Return on Net Nonoperating Assets (RNNOA)	-36.23%	-36.70%	-28.18%	-74.79%	-57.79%	-68.85%	0.00%	-62.16%	-7.71%	-1.37%	-0.42%
Return on Equity (ROE)	37.05%	33.01%	18.17%	33.47%	27.06%	31.43%	0.00%	31.92%	12.50%	7.17%	1.96%
Cash Return on Invested Capital (CROIC)	58.79%	61.44%	71.52%	110.69%	81.72%	89.85%	0.00%	-105.91%	-77.95%	8.55%	-0.92%
Operating Return on Assets (OROA)	36.57%	30.77%	26.77%	34.85%	28.03%	30.39%	0.00%	17.61%	13.84%	8.73%	5.36%
Return on Assets (ROA)	24.47%	22.38%	12.63%	23.51%	18.77%	21.53%	0.00%	11.63%	9.49%	5.62%	1.54%
Return on Common Equity (ROCE)	37.05%	33.01%	18.17%	33.47%	27.06%	31.43%	0.00%	31.92%	11.83%	6.51%	1.78%
Return on Equity Simple (ROE_SIMPLE)	33.71%	30.75%	17.22%	32.27%	28.58%	28.23%	0.00%	15.96%	11.99%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	94	100	62	124	98	124	69	69	58	37	10
NOPAT Margin	10.24%	9.95%	5.88%	10.44%	9.20%	10.90%	6.88%	6.88%	6.29%	4.28%	1.12%
Net Nonoperating Expense Percent (NNEP)	0.48%	-0.03%	0.47%	0.79%	1.12%	0.37%	0.00%	0.45%	2.61%	3.48%	0.75%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	10.44%	6.58%	1.89%
Cost of Revenue to Revenue	17.39%	17.91%	17.13%	16.88%	17.67%	18.43%	19.42%	19.42%	19.18%	18.87%	21.71%
SG&A Expenses to Revenue	22.75%	23.28%	25.31%	23.13%	25.24%	23.02%	26.27%	26.27%	27.90%	30.81%	36.46%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	67.19%	68.31%	70.22%	67.29%	137.09%	66.02%	69.81%	69.81%	70.71%	73.37%	74.25%
Earnings before Interest and Taxes (EBIT)	141	138	133	187	150	176	105	105	93	65	40
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	151	151	149	204	173	198	126	126	115	80	73
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	5.81	9.18	4.89	7.05	4.92	3.67	0.00	2.35	1.93	1.28	0.67
Price to Tangible Book Value (P/TBV)	7.25	10.89	5.72	8.05	5.67	4.12	0.00	2.66	4.34	2.88	1.36
Price to Revenue (P/Rev)	1.78	2.97	1.70	2.32	1.63	1.43	1.02	1.02	1.11	0.80	0.38
Price to Earnings (P/E)	17.23	29.84	28.41	21.84	0.00	13.01	14.73	14.73	16.07	16.18	33.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.80%	3.35%	3.52%	4.58%	0.00%	7.69%	6.79%	6.79%	6.22%	6.18%	3.03%
Enterprise Value to Invested Capital (EV/IC)	10.81	18.79	13.18	21.88	12.80	10.10	0.00	5.02	2.15	1.35	0.60
Enterprise Value to Revenue (EV/Rev)	1.62	2.79	1.46	2.08	1.41	1.15	0.00	0.73	1.00	0.67	0.29
Enterprise Value to EBITDA (EV/EBITDA)	9.82	18.60	10.29	12.15	8.64	6.60	0.00	5.80	7.99	7.21	3.64
Enterprise Value to EBIT (EV/EBIT)	10.52	20.43	11.54	13.25	9.97	7.45	0.00	6.98	9.89	8.81	6.61
Enterprise Value to NOPAT (EV/NOPAT)	15.82	28.07	24.85	19.96	15.33	10.60	0.00	10.67	15.89	15.76	25.54
Enterprise Value to Operating Cash Flow (EV/OCF)	13.35	20.52	12.36	16.29	11.81	8.17	0.00	7.06	15.10	9.44	11.82
Enterprise Value to Free Cash Flow (EV/FCFF)	19.72	31.84	16.10	19.52	15.91	11.82	0.00	0.00	0.00	15.76	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.04	0.04	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.50	-0.53	-0.61	-0.70	-0.69	-0.69	0.00	-0.66	-0.44	-0.27	-0.26
Leverage Ratio	1.51	1.47	1.44	1.42	1.44	1.46	0.00	1.37	1.32	1.28	1.27
Compound Leverage Factor	1.53	1.49	1.46	1.46	1.45	1.48	0.00	1.42	1.45	1.49	1.32
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.77%	3.77%	2.33%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.77%	3.77%	2.33%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8.90%	8.90%	8.86%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	87.33%	87.33%	88.81%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.29	0.19
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-1.38	-1.99	-1.99
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.40	0.63	1.35
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-2.74	-4.35	-13.96
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	11.18	16.57	10.93	14.74	10.58	8.88	0.00	7.44	6.56	5.07	3.92
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5.31%	9.25%	9.16%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.86	2.01	2.41	2.64	2.42	2.53	0.00	2.67	2.00	2.00	2.24
Quick Ratio	1.09	1.27	1.75	1.87	1.73	1.86	0.00	2.01	1.30	1.30	1.27
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	75	88	95	127	94	111	198	-77	-224	37	-3.98
Operating Cash Flow to CapEx	473.44%	418.79%	937.82%	1,376.39%	765.67%	1,063.10%	999.73%	613.90%	609.37%	609.37%	225.34%
Free Cash Flow to Firm to Interest Expense	5,030.17	198.69	2,064.72	3,526.15	1,424.98	218.53	1,033.54	-402.84	-853.30	130.02	-4.73
Operating Cash Flow to Interest Expense	7,431.07	308.31	2,690.74	4,225.53	1,920.20	316.37	541.16	541.16	232.79	217.05	26.54
Operating Cash Flow Less CapEx to Interest Expense	5,861.47	234.69	2,403.83	3,918.53	1,669.41	286.61	487.03	453.01	194.59	181.43	14.76
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	2.37	2.25	2.12	2.22	1.98	1.96	0.00	1.67	1.37	1.14	1.24
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	2.87	2.75	2.81	2.77	2.49	2.63	0.00	2.89	2.58	2.31	2.33
Fixed Asset Turnover	11.54	10.63	10.26	12.21	11.33	11.60	0.00	10.21	9.58	9.04	9.79
Accounts Payable Turnover	17.92	18.88	17.23	18.47	16.69	13.61	0.00	17.55	15.34	13.45	13.73
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	127.28	132.61	129.93	131.72	146.83	138.88	0.00	126.30	141.32	157.89	156.60
Days Payable Outstanding (DPO)	20.37	19.33	21.19	19.76	21.87	26.81	0.00	20.80	23.79	27.13	26.57
Cash Conversion Cycle (CCC)	106.91	113.28	108.75	111.96	124.96	112.07	0.00	105.50	117.53	130.75	130.02
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	138	150	116	113	117	130	0.00	146	428	428	442
Invested Capital Turnover	7.16	7.01	7.89	10.37	9.22	9.20	0.00	13.67	3.21	2.00	2.13
Increase / (Decrease) in Invested Capital	19	12	-33	-2.80	3.60	13	-130	146	282	0.00	14
Enterprise Value (EV)	1,488	2,809	1,530	2,478	1,497	1,310	0.00	733	921	576	264
Market Capitalization	1,631	2,985	1,777	2,756	1,731	1,622	1,022	1,022	1,025	680	355
Book Value per Share	$21.99	$26.68	$15.14	$16.31	$16.25	$20.88	$0.00	$22.62	$27.82	$27.92	$29.16
Tangible Book Value per Share	$17.63	$22.49	$12.95	$14.29	$14.10	$18.60	$0.00	$20.03	$12.34	$12.39	$14.33
Total Capital	281	325	363	391	352	442	0.00	434	609	609	600
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	23	23	14
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-143	-176	-247	-278	-235	-312	0.00	-288	-159	-159	-144
Capital Expenditures (CapEx)	24	33	13	11	17	15	10	17	10	10	9.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-30	-36	-48	-34	-42	-55	0.00	-48	-19	-19	15
Debt-free Net Working Capital (DFNWC)	113	139	199	244	193	257	0.00	241	163	163	174
Net Working Capital (NWC)	113	139	199	244	193	257	0.00	241	140	140	160
Net Nonoperating Expense (NNE)	-0.62	0.05	-0.99	-2.08	-2.88	-1.02	-0.64	-0.64	-5.84	-5.52	-1.13
Net Nonoperating Obligations (NNO)	-143	-176	-247	-278	-235	-312	0.00	-288	-159	-159	-144
Total Depreciation and Amortization (D&A)	9.98	13	16	17	23	23	21	21	22	15	33
Debt-free, Cash-free Net Working Capital to Revenue	-3.31%	-3.62%	-4.60%	-2.88%	-3.93%	-4.82%	0.00%	-4.79%	-2.09%	-2.25%	1.67%
Debt-free Net Working Capital to Revenue	12.29%	13.85%	19.00%	20.49%	18.21%	22.67%	0.00%	24.09%	17.65%	19.02%	18.79%
Net Working Capital to Revenue	12.29%	13.85%	19.00%	20.49%	18.21%	22.67%	0.00%	24.09%	15.15%	16.33%	17.28%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.86	$4.14	$2.57	$5.24	$4.44	$5.89	$0.00	$0.00	$3.31	$0.00	$0.58
Adjusted Weighted Average Basic Shares Outstanding	50.92M	24.19M	24.35M	24.11M	22.64M	21.16M	0.00	0.00	19.25M	0.00	18.54M
Adjusted Diluted Earnings per Share	$1.80	$3.99	$2.53	$5.12	$4.41	$5.86	$0.00	$0.00	$3.30	$0.00	$0.58
Adjusted Weighted Average Diluted Shares Outstanding	52.71M	25.05M	24.71M	24.64M	22.82M	21.26M	0.00	0.00	19.35M	0.00	18.57M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	47.78M	24.50M	24.05M	23.32M	21.55M	20.85M	0.00	0.00	18.90M	0.00	18.46M
Normalized Net Operating Profit after Tax (NOPAT)	94	100	93	124	98	124	69	69	58	37	36
Normalized NOPAT Margin	10.24%	9.95%	8.86%	10.44%	9.20%	10.90%	6.88%	6.88%	6.29%	4.28%	3.85%
Pre Tax Income Margin	15.52%	13.77%	12.86%	16.10%	14.19%	15.68%	10.88%	10.88%	11.12%	8.94%	4.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	9,432.53	309.72	2,880.46	5,197.75	2,275.17	346.98	547.00	547.00	355.26	232.43	47.45
NOPAT to Interest Expense	6,270.43	225.43	1,337.89	3,448.42	1,479.54	243.87	357.85	357.85	221.17	130.02	12.29
EBIT Less CapEx to Interest Expense	7,862.93	236.10	2,593.54	4,890.75	2,024.38	317.22	492.87	458.85	317.06	196.81	35.67
NOPAT Less CapEx to Interest Expense	4,700.83	151.81	1,050.98	3,141.42	1,228.75	214.11	303.72	269.70	182.97	94.40	0.51
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	15.24%
Augmented Payout Ratio	64.62%	64.58%	79.96%	83.48%	149.22%	45.75%	36.60%	36.60%	14.81%	22.45%	254.91%

This table displays calculated financial ratios and metrics derived from USANA Health Sciences' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/30/2023	3/30/2024	6/29/2024	9/28/2024	12/28/2024	3/29/2025	6/28/2025	9/27/2025	1/3/2026	4/4/2026
DEI Shares Outstanding	-	-	-	-	-	19,059,572.00	18,904,526.00	18,623,075.00	18,271,836.00	18,280,857.00	18,456,935.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	19,059,572.00	18,904,526.00	18,623,075.00	18,271,836.00	18,280,857.00	18,456,935.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	0.23	0.50	0.52	-0.36	-0.10	0.41
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-8.54%	-3.02%	-8.28%	-10.64%	-6.16%	-3.38%	9.54%	10.79%	6.72%	5.89%	0.27%
EBITDA Growth	-17.16%	14.76%	-7.54%	-22.09%	-8.37%	-55.84%	-9.80%	22.98%	-51.88%	4.63%	-6.06%
EBIT Growth	-20.13%	11.58%	-8.48%	-28.98%	-13.04%	-67.21%	-32.92%	5.52%	-91.85%	-51.34%	-7.06%
NOPAT Growth	-33.11%	20.58%	-13.08%	-41.47%	-8.61%	-76.87%	-42.21%	0.73%	-151.11%	-141.31%	-28.22%
Net Income Growth	-23.99%	31.04%	-10.04%	-39.67%	-6.52%	-73.26%	-43.82%	0.12%	-162.81%	-135.57%	-25.09%
EPS Growth	-24.36%	31.82%	-9.47%	-39.33%	-5.08%	-73.56%	-43.02%	-3.70%	-164.29%	-130.43%	-16.33%
Operating Cash Flow Growth	-23.66%	-59.53%	37.79%	-16.34%	32.83%	-77.77%	-12.45%	52.92%	-106.64%	-158.60%	-36.97%
Free Cash Flow Firm Growth	0.00%	0.00%	-89.91%	-109.47%	-62.32%	101.33%	-12,516.84%	-12,588.21%	-6,900.29%	-547.21%	94.90%
Invested Capital Growth	-0.55%	192.75%	8.18%	6.61%	2.99%	0.00%	147.01%	141.52%	159.34%	3.35%	4.39%
Revenue Q/Q Growth	-10.43%	3.62%	3.04%	-6.55%	-5.94%	6.69%	16.82%	-5.49%	-9.40%	5.86%	10.62%
EBITDA Q/Q Growth	-22.74%	32.85%	2.96%	-21.57%	-9.14%	-38.07%	125.67%	-1.77%	-64.95%	34.65%	102.63%
EBIT Q/Q Growth	-27.56%	33.69%	2.67%	-28.57%	-11.30%	-49.60%	110.06%	12.36%	-93.15%	200.79%	301.26%
NOPAT Q/Q Growth	-38.17%	56.81%	-1.37%	-38.79%	-3.46%	-60.31%	146.39%	6.69%	-148.99%	67.92%	528.11%
Net Income Q/Q Growth	-34.38%	47.76%	-1.37%	-36.92%	1.68%	-57.73%	107.18%	12.42%	-163.79%	76.06%	536.30%
EPS Q/Q Growth	-33.71%	47.46%	-1.15%	-37.21%	3.70%	-58.93%	113.04%	6.12%	-169.23%	80.56%	685.71%
Operating Cash Flow Q/Q Growth	132.79%	-26.36%	-32.05%	-54.82%	269.64%	-80.41%	167.62%	-21.08%	-116.05%	-72.87%	387.88%
Free Cash Flow Firm Q/Q Growth	-47.87%	-2,602.85%	131.61%	-197.69%	307.43%	-11.93%	-7,057.38%	0.18%	-11.17%	94.21%	20.62%
Invested Capital Q/Q Growth	-3.16%	161.81%	3.23%	3.94%	-6.44%	154.20%	-0.07%	1.63%	0.46%	1.30%	0.94%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	80.07%	80.86%	81.09%	81.05%	80.39%	81.95%	78.98%	78.72%	77.15%	78.16%	76.25%
EBITDA Margin	10.78%	13.82%	12.98%	10.90%	10.53%	5.53%	10.69%	11.11%	4.30%	5.47%	10.01%
Operating Margin	8.25%	10.95%	10.83%	8.38%	7.79%	3.84%	6.28%	7.09%	0.57%	1.69%	5.54%
EBIT Margin	8.36%	10.79%	10.75%	8.22%	7.75%	3.66%	6.58%	7.83%	0.59%	1.68%	6.10%
Profit (Net Income) Margin	5.32%	7.58%	7.26%	4.90%	5.30%	2.10%	3.72%	4.43%	-3.12%	-0.71%	2.78%
Tax Burden Percent	55.27%	63.00%	61.00%	51.64%	57.00%	43.00%	55.50%	55.50%	-371.35%	-38.19%	45.00%
Interest Burden Percent	115.08%	111.57%	110.72%	115.51%	119.94%	133.36%	101.90%	101.95%	141.82%	109.78%	101.29%
Effective Tax Rate	44.73%	37.00%	39.00%	48.36%	43.00%	57.00%	44.50%	44.50%	471.35%	138.19%	55.00%
Return on Invested Capital (ROIC)	25.84%	22.16%	35.74%	21.74%	23.10%	3.30%	10.18%	0.00%	0.00%	-1.37%	5.29%
ROIC Less NNEP Spread (ROIC-NNEP)	25.26%	21.49%	35.27%	21.35%	22.59%	2.70%	9.93%	0.00%	0.00%	-1.28%	4.82%
Return on Net Nonoperating Assets (RNNOA)	-15.87%	-9.41%	-22.98%	-13.77%	-15.13%	-0.73%	-4.43%	0.00%	0.00%	0.33%	-1.25%
Return on Equity (ROE)	9.97%	12.75%	12.77%	7.97%	7.97%	2.57%	5.74%	0.00%	0.00%	-1.04%	4.04%
Cash Return on Invested Capital (CROIC)	0.00%	-77.95%	25.62%	21.83%	26.22%	8.55%	-74.65%	-82.88%	-88.68%	-0.92%	-2.45%
Operating Return on Assets (OROA)	13.41%	14.78%	15.68%	11.65%	10.50%	4.18%	8.38%	0.00%	0.00%	2.09%	7.61%
Return on Assets (ROA)	8.53%	10.39%	10.59%	6.95%	7.18%	2.40%	4.74%	0.00%	0.00%	-0.88%	3.47%
Return on Common Equity (ROCE)	9.97%	12.07%	12.77%	7.97%	7.97%	2.33%	5.46%	0.00%	0.00%	-0.95%	3.68%
Return on Equity Simple (ROE_SIMPLE)	12.72%	0.00%	12.39%	10.75%	10.19%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	9.73	15	15	9.21	8.89	3.53	8.70	9.28	-4.55	-1.46	6.24
NOPAT Margin	4.56%	6.90%	6.61%	4.33%	4.44%	1.65%	3.49%	3.93%	-2.13%	-0.64%	2.50%
Net Nonoperating Expense Percent (NNEP)	0.58%	0.67%	0.48%	0.39%	0.51%	0.60%	0.25%	0.48%	-0.83%	-0.09%	0.47%
Return On Investment Capital (ROIC_SIMPLE)	-	2.75%	-	-	-	0.64%	1.57%	1.75%	-0.86%	-0.27%	1.12%
Cost of Revenue to Revenue	19.93%	19.14%	18.91%	18.95%	19.61%	18.05%	21.02%	21.28%	22.85%	21.84%	23.75%
SG&A Expenses to Revenue	29.67%	26.53%	28.23%	30.22%	30.61%	34.34%	36.64%	34.73%	40.22%	34.52%	35.27%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	71.82%	69.90%	70.26%	72.67%	72.60%	78.11%	72.70%	71.63%	76.58%	76.47%	70.70%
Earnings before Interest and Taxes (EBIT)	18	24	24	17	16	7.82	16	18	1.27	3.81	15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	23	31	30	23	21	12	27	26	9.18	12	25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.41	1.93	1.86	1.68	1.36	1.28	0.99	1.09	0.99	0.67	0.57
Price to Tangible Book Value (P/TBV)	2.67	4.34	2.04	1.85	1.48	2.88	2.20	2.38	2.12	1.36	1.13
Price to Revenue (P/Rev)	1.22	1.11	1.03	0.98	0.84	0.80	0.60	0.00	0.00	0.38	0.34
Price to Earnings (P/E)	18.91	16.07	14.98	15.65	13.29	16.18	15.05	0.00	0.00	33.03	35.15
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	5.29%	6.22%	6.68%	6.39%	7.52%	6.18%	6.64%	0.00%	0.00%	3.03%	2.84%
Enterprise Value to Invested Capital (EV/IC)	5.05	2.15	3.47	2.94	2.13	1.35	0.99	1.11	0.98	0.60	0.48
Enterprise Value to Revenue (EV/Rev)	0.89	1.00	0.67	0.61	0.41	0.67	0.48	0.00	0.00	0.29	0.23
Enterprise Value to EBITDA (EV/EBITDA)	7.40	7.99	5.41	5.07	3.49	7.21	5.49	0.00	0.00	3.64	3.01
Enterprise Value to EBIT (EV/EBIT)	9.10	9.89	6.62	6.33	4.40	8.81	7.38	0.00	0.00	6.61	5.53
Enterprise Value to NOPAT (EV/NOPAT)	14.87	15.89	10.78	10.76	7.40	15.76	13.97	0.00	0.00	25.54	26.48
Enterprise Value to Operating Cash Flow (EV/OCF)	9.69	15.10	7.96	7.16	4.40	9.44	7.19	0.00	0.00	11.82	12.90
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	14.09	13.92	8.23	15.76	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.04	0.00	0.00	0.00	0.04	0.04	0.00	0.00	0.02	0.02
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.63	-0.44	-0.65	-0.64	-0.67	-0.27	-0.45	-0.44	-0.46	-0.26	-0.26
Leverage Ratio	1.31	1.32	1.29	1.26	1.27	1.28	1.27	1.24	1.25	1.27	1.26
Compound Leverage Factor	1.51	1.47	1.43	1.45	1.52	1.70	1.29	1.27	1.78	1.40	1.28
Debt to Total Capital	0.00%	3.77%	0.26%	0.00%	0.00%	3.77%	3.79%	0.00%	0.00%	2.33%	2.30%
Short-Term Debt to Total Capital	0.00%	3.77%	0.26%	0.00%	0.00%	3.77%	3.79%	0.00%	0.00%	2.33%	2.30%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	8.90%	0.00%	0.00%	0.00%	8.90%	8.92%	9.31%	9.20%	8.86%	8.42%
Common Equity to Total Capital	100.00%	87.33%	99.74%	100.00%	100.00%	87.33%	87.29%	90.69%	90.80%	88.81%	89.28%
Debt to EBITDA	0.00	0.20	0.01	0.00	0.00	0.29	0.30	0.00	0.00	0.19	0.20
Net Debt to EBITDA	0.00	-1.38	-2.94	0.00	0.00	-1.99	-2.03	0.00	0.00	-1.99	-2.09
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.40	0.02	0.00	0.00	0.63	0.76	0.00	0.00	1.35	1.73
Net Debt to NOPAT	0.00	-2.74	-5.87	0.00	0.00	-4.35	-5.18	0.00	0.00	-13.96	-18.37
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.39	6.26	7.46	7.44	6.09	4.82	4.31	3.55	3.30	3.76	3.80
Noncontrolling Interest Sharing Ratio	0.00%	5.31%	0.00%	0.00%	0.00%	9.25%	4.99%	4.96%	4.80%	9.16%	8.94%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.47	2.00	3.74	4.03	3.93	2.00	2.05	2.15	2.23	2.24	2.51
Quick Ratio	2.73	1.30	2.92	3.20	3.18	1.30	1.31	1.24	1.22	1.27	1.47
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	11	-266	1.98	-1.93	4.01	3.53	-246	-245	-273	-16	-13
Operating Cash Flow to CapEx	1,529.16%	574.12%	552.94%	299.14%	1,263.22%	321.03%	552.34%	243.05%	-61.32%	0.00%	375.78%
Free Cash Flow to Firm to Interest Expense	247.39	-1,836.23	38.04	-37.89	81.79	27.36	-597.54	-946.55	-5,562.27	-128.34	-52.22
Operating Cash Flow to Interest Expense	517.07	112.92	340.06	156.67	602.73	44.85	37.67	47.17	-40.02	-27.56	40.66
Operating Cash Flow Less CapEx to Interest Expense	483.26	93.26	278.56	104.29	555.02	30.88	30.85	27.76	-105.29	-18.54	29.84
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.60	1.37	1.46	1.42	1.35	1.14	1.27	0.00	0.00	1.24	1.25
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	2.84	2.58	2.73	2.72	2.66	2.31	2.54	0.00	0.00	2.33	2.45
Fixed Asset Turnover	9.75	9.58	9.24	9.05	8.92	9.04	9.11	0.00	0.00	9.79	9.81
Accounts Payable Turnover	18.37	15.34	18.24	21.14	20.17	13.45	15.34	0.00	0.00	13.73	13.76
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	128.55	141.32	133.60	134.28	137.24	157.89	143.81	0.00	0.00	156.60	149.20
Days Payable Outstanding (DPO)	19.87	23.79	20.01	17.27	18.10	27.13	23.79	0.00	0.00	26.57	26.52
Cash Conversion Cycle (CCC)	108.69	117.53	113.59	117.01	119.14	130.75	120.02	0.00	0.00	130.02	122.68
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	163	428	173	180	168	428	427	434	436	442	446
Invested Capital Turnover	5.67	3.21	5.41	5.02	5.20	2.00	2.92	0.00	0.00	2.13	2.12
Increase / (Decrease) in Invested Capital	-0.91	282	13	11	4.89	0.00	254	254	268	14	19
Enterprise Value (EV)	824	921	601	529	358	576	423	483	429	264	214
Market Capitalization	1,131	1,025	928	862	722	680	525	580	521	355	312
Book Value per Share	$24.37	$27.82	$26.08	$26.89	$27.98	$27.92	$28.02	$28.52	$28.90	$29.16	$29.45
Tangible Book Value per Share	$21.97	$12.34	$23.68	$24.50	$25.54	$12.39	$12.61	$13.11	$13.44	$14.33	$14.98
Total Capital	470	609	501	512	533	609	607	586	582	600	609
Total Debt	0.00	23	1.32	0.00	0.00	23	23	0.00	0.00	14	14
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-307	-159	-327	-332	-365	-159	-157	-151	-145	-144	-149
Capital Expenditures (CapEx)	1.45	2.85	3.20	2.67	2.34	1.80	2.80	5.03	3.20	-1.11	2.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-29	-19	-19	-17	-28	-19	-13	-11	0.05	15	28
Debt-free Net Working Capital (DFNWC)	278	163	310	315	336	163	167	140	145	174	191
Net Working Capital (NWC)	278	140	308	315	336	140	144	140	145	160	177
Net Nonoperating Expense (NNE)	-1.62	-1.51	-1.49	-1.22	-1.71	-0.95	-0.59	-1.17	2.12	0.14	-0.72
Net Nonoperating Obligations (NNO)	-307	-159	-327	-332	-365	-159	-157	-151	-145	-144	-149
Total Depreciation and Amortization (D&A)	5.16	6.71	5.08	5.70	5.56	4.00	10	7.74	7.92	8.56	9.79
Debt-free, Cash-free Net Working Capital to Revenue	-3.14%	-2.09%	-2.06%	-1.97%	-3.30%	-2.25%	-1.44%	0.00%	0.00%	1.67%	3.05%
Debt-free Net Working Capital to Revenue	29.95%	17.65%	34.40%	36.02%	39.03%	19.02%	19.06%	0.00%	0.00%	18.79%	20.63%
Net Working Capital to Revenue	29.95%	15.15%	34.25%	36.02%	39.03%	16.33%	16.44%	0.00%	0.00%	17.28%	19.12%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.59	$0.88	$0.86	$0.55	$0.56	$0.23	$0.49	$0.52	($0.36)	($0.07)	$0.41
Adjusted Weighted Average Basic Shares Outstanding	19.25M	19.25M	19.17M	19.07M	19.08M	19.10M	19.05M	18.51M	18.29M	18.54M	18.40M
Adjusted Diluted Earnings per Share	$0.59	$0.87	$0.86	$0.54	$0.56	$0.23	$0.49	$0.52	($0.36)	($0.07)	$0.41
Adjusted Weighted Average Diluted Shares Outstanding	19.37M	19.35M	19.30M	19.16M	19.08M	19.16M	19.09M	18.54M	18.29M	18.57M	18.41M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	19.13M	18.90M	19.05M	19.05M	19.06M	0.00	18.62M	18.27M	18.28M	18.46M	18.46M
Normalized Net Operating Profit after Tax (NOPAT)	9.73	15	15	9.21	8.89	5.75	8.70	9.28	0.86	2.67	9.71
Normalized NOPAT Margin	4.56%	6.90%	6.61%	4.33%	4.44%	2.69%	3.49%	3.93%	0.40%	1.18%	3.88%
Pre Tax Income Margin	9.62%	12.04%	11.90%	9.49%	9.29%	4.88%	6.71%	7.98%	0.84%	1.85%	6.18%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	414.91	164.49	470.90	342.96	316.63	60.62	39.97	71.26	25.82	30.94	63.62
NOPAT to Interest Expense	226.30	105.23	289.42	180.62	181.49	27.36	21.16	35.83	-92.76	-11.86	26.01
EBIT Less CapEx to Interest Expense	381.09	144.82	409.40	290.59	268.92	46.65	33.15	51.85	-39.45	39.96	52.80
NOPAT Less CapEx to Interest Expense	192.49	85.57	227.92	128.25	133.77	13.39	14.34	16.42	-158.03	-2.83	15.19
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	15.24%	34.17%
Augmented Payout Ratio	19.39%	14.81%	33.97%	38.20%	17.38%	22.45%	35.33%	0.00%	0.00%	254.91%	200.44%

Financials Breakdown Chart

Key Financial Trends

USANA Health Sciences (NYSE:USNA) showed a sharp rebound in Q1 2026, but the longer-term picture remains mixed. Revenue and profit improved materially versus the weak prior quarter, and operating cash flow turned positive again. However, margins are still volatile, cash balances have been declining from the unusually high 2024 level, and the company continues to carry a meaningful amount of intangible assets and redeemable noncontrolling interest on the balance sheet.

Revenue rebounded quarter over quarter: Q1 2026 revenue rose to $250.2 million from $226.2 million in Q4 2025, a solid sequential improvement.
Profitability recovered: Net income attributable to common shareholders improved to $7.5 million in Q1 2026 from a $1.8 million loss in Q4 2025.
Operating income returned to a healthier level: Operating income was $13.9 million in Q1 2026 versus just $3.8 million in Q4 2025.
Operating cash flow turned positive again: USANA generated $9.8 million in operating cash flow in Q1 2026 after posting negative operating cash flow in Q4 2025.
Liquidity remains reasonable: Cash and equivalents totaled $162.8 million at the end of Q1 2026, giving the company a sizable liquidity cushion.
Year-over-year sales growth is intact: Q1 2026 revenue was up from $249.5 million in Q1 2025, showing modest annual growth.
EPS was flat: Basic and diluted EPS were both $0.41 in Q1 2026, indicating improvement but not a dramatic earnings breakout.
Inventory remains elevated: Inventories were $96.4 million in Q1 2026, which investors may want to watch for any signs of buildup relative to demand.
The balance sheet still contains a large goodwill and intangible asset base: Goodwill and intangibles totaled about $267.0 million, which can be a vulnerability if growth weakens.
Margins remain pressured compared with the stronger 2024 period: Q1 2026 operating margin was much lower than the best quarters in the prior year, reflecting continued cost pressure.
Cash is down sharply from last year’s peak: Cash and equivalents fell from $364.9 million in Q3 2024 to $162.8 million in Q1 2026, reducing balance-sheet flexibility.
Volatility has been significant over the last several quarters: USANA swung from strong profitability in early 2024 to losses in late 2025, suggesting demand and expense trends remain unstable.
Redeemable noncontrolling interest is sizable: The company reported $51.2 million of redeemable noncontrolling interest, which adds complexity to the equity structure.

Bottom line: USANA’s latest quarter suggests the business is stabilizing after a difficult stretch, with better revenue, profits, and cash generation. Still, investors should remain cautious until the company shows more consistent margin improvement and sustained free-cash-flow strength across multiple quarters.

07/03/26 02:15 PM ETAI Generated. May Contain Errors.

USANA Health Sciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, USANA Health Sciences' fiscal year ends in January. Their fiscal year 2026 ended on January 3, 2026.

USANA Health Sciences' net income appears to be on a downward trend, with a most recent value of $11.48 million in 2025, falling from $94.67 million in 2015. The previous period was $42.06 million in 2024. See where experts think USANA Health Sciences is headed by visiting USANA Health Sciences' forecast page.

USANA Health Sciences' total operating income in 2025 was $37.43 million, based on the following breakdown:

Total Gross Profit: $724.41 million
Total Operating Expenses: $686.97 million

Over the last 10 years, USANA Health Sciences' total revenue changed from $918.50 million in 2015 to $925.26 million in 2025, a change of 0.7%.

USANA Health Sciences' total liabilities were at $156.64 million at the end of 2025, a 3.2% decrease from 2024, and a 30.1% increase since 2014.

In the past 10 years, USANA Health Sciences' cash and equivalents has ranged from $111.13 million in 2014 to $311.92 million in 2020, and is currently $158.38 million as of their latest financial filing in 2025.

Over the last 10 years, USANA Health Sciences' book value per share changed from 21.99 in 2015 to 29.16 in 2025, a change of 32.6%.

Related Companies

Financial statements for NYSE:USNA last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

USANA Health Sciences (USNA) Financials

Financials Breakdown Chart

Key Financial Trends

USANA Health Sciences Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

USANA Health Sciences (USNA) Financials

Annual Income Statements for USANA Health Sciences

Quarterly Income Statements for USANA Health Sciences

Annual Cash Flow Statements for USANA Health Sciences

Quarterly Cash Flow Statements for USANA Health Sciences

Annual Balance Sheets for USANA Health Sciences

Quarterly Balance Sheets for USANA Health Sciences

Annual Metrics And Ratios for USANA Health Sciences

Quarterly Metrics And Ratios for USANA Health Sciences

Financials Breakdown Chart

Key Financial Trends

USANA Health Sciences Financials - Frequently Asked Questions

When does USANA Health Sciences' financial year end?

How has USANA Health Sciences' net income changed over the last 10 years?

What is USANA Health Sciences' operating income?

How has USANA Health Sciences' revenue changed over the last 10 years?

How much debt does USANA Health Sciences have?

How much cash does USANA Health Sciences have?

How has USANA Health Sciences' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools